Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.

Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T.

Prostate Cancer Prostatic Dis. 2018 Nov 28. doi: 10.1038/s41391-018-0112-3. [Epub ahead of print]

PMID:
30487644
2.

Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.

Bartkowiak D, Thamm R, Bottke D, Siegmann A, Böhmer D, Budach V, Wiegel T.

Acta Oncol. 2018 Mar;57(3):362-367. doi: 10.1080/0284186X.2017.1364869. Epub 2017 Aug 17.

PMID:
28816074
3.

The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.

Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T.

Radiother Oncol. 2016 Jan;118(1):131-5. doi: 10.1016/j.radonc.2015.10.028. Epub 2015 Nov 30.

PMID:
26653358
4.

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S.

Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.

PMID:
23151842
5.

Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.

Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16. doi: 10.1016/j.ijrobp.2008.06.1922. Epub 2008 Oct 27.

PMID:
18963539
6.

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ.

J Clin Oncol. 2016 Oct 20;34(30):3648-3654. doi: 10.1200/JCO.2016.67.9647.

PMID:
27528718
7.

Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.

Budäus L, Schiffmann J, Graefen M, Huland H, Tennstedt P, Siegmann A, Böhmer D, Budach V, Bartkowiak D, Wiegel T.

Strahlenther Onkol. 2017 Sep;193(9):692-699. doi: 10.1007/s00066-017-1140-y. Epub 2017 May 3.

PMID:
28470414
8.

[Adjuvant vs. salvage radiotherapy after radical prostatectomy].

Bartkowiak D, Schrader AJ, Wiegel T.

Aktuelle Urol. 2015 Jan;46(1):52-8. doi: 10.1055/s-0034-1395656. Epub 2015 Feb 6. Review. German.

PMID:
25658231
9.

Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.

Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):755-63.

PMID:
12788182
10.

Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.

Ploussard G, Staerman F, Pierrevelcin J, Larue S, Villers A, Ouzzane A, Bastide C, Gaschignard N, Buge F, Pfister C, Bonniol R, Rebillard X, Fadli S, Mottet N, Saint F, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Soulie M, Salomon L; Committee of Cancerology (CCAFU) of the Association of French Urology (AFU).

World J Urol. 2014 Oct;32(5):1331-8. doi: 10.1007/s00345-013-1214-0. Epub 2013 Nov 24.

PMID:
24270970
11.

Contemporary salvage post prostatectomy radiotherapy: Early implementation improves biochemical control.

Kneebone A, Hruby G, Harris G, Rasiah K, Vass J, Whalley D, McCloud P, Louw S, Guo L, Eade T.

J Med Imaging Radiat Oncol. 2018 Apr;62(2):240-247. doi: 10.1111/1754-9485.12684. Epub 2017 Oct 28.

PMID:
29080287
12.

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.

Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]

PMID:
28779974
13.

Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.

Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):216-21. doi: 10.1038/pcan.2016.9. Epub 2016 Mar 8.

PMID:
26951715
14.

Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.

Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D, Hinkelbein W, Wiegel T.

World J Urol. 2013 Apr;31(2):423-8. doi: 10.1007/s00345-012-0860-y. Epub 2012 Mar 30.

PMID:
22460203
15.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
16.

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience.

Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA.

Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30236-7. doi: 10.1016/j.clgc.2017.07.026. [Epub ahead of print]

PMID:
28864223
17.

Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?

Pai HH, Eldridge B, Bishop D, Alexander A, Lesperance M, Blood P, Lim J, Ludgate C.

Can J Urol. 2009 Apr;16(2):4541-52.

PMID:
19364426
18.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.

PMID:
25445556
19.

High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.

Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, De Meerleer G.

Eur Urol. 2011 Oct;60(4):842-9. doi: 10.1016/j.eururo.2011.04.021. Epub 2011 Apr 16.

PMID:
21514039
20.

HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.

Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.

Urol Oncol. 2012 Sep;30(5):577-83. doi: 10.1016/j.urolonc.2010.08.019. Epub 2011 Feb 2.

PMID:
21292508

Supplemental Content

Support Center